title: Recent perspectives on the delivery of biologics to back of the eye.
abstract: Biologics are generally macromolecules, large in size with poor stability in biological environments. Delivery of biologics to tissues at the back of the eye remains a challenge. To overcome these challenges and treat posterior ocular diseases, several novel approaches have been developed. Nanotechnology-based delivery systems, like drug encapsulation technology, macromolecule implants and gene delivery are under investigation. We provide an overview of emerging technologies for biologics delivery to back of the eye tissues. Moreover, new biologic drugs currently in clinical trials for ocular neovascular diseases have been discussed. Areas covered: Anatomy of the eye, posterior segment disease and diagnosis, barriers to biologic delivery, ocular pharmacokinetic, novel biologic delivery system Expert opinion: Anti-VEGF therapy represents a significant advance in developing biologics for the treatment of ocular neovascular diseases. Various strategies for biologic delivery to posterior ocular tissues are under development with some in early or late stages of clinical trials. Despite significant progress in the delivery of biologics, there is unmet need to develop sustained delivery of biologics with nearly zero-order release kinetics to the back of the eye tissues. In addition, elevated intraocular pressure associated with frequent intravitreal injections of macromolecules is another concern that needs to be addressed.
authors: a Division of Pharmaceutical Sciences, School of Pharmacy , University of Missouri-Kansas City , Kansas City , MO , USA.
authors: Mary
authors: M
authors: Joseph
authors: a Division of Pharmaceutical Sciences, School of Pharmacy , University of Missouri-Kansas City , Kansas City , MO , USA.
authors: Hoang M
authors: HM
authors: Trinh
authors: a Division of Pharmaceutical Sciences, School of Pharmacy , University of Missouri-Kansas City , Kansas City , MO , USA.|b Formulations R&D , RiconPharma LLC , Denville , NJ , USA.
authors: Kishore
authors: K
authors: Cholkar
authors: a Division of Pharmaceutical Sciences, School of Pharmacy , University of Missouri-Kansas City , Kansas City , MO , USA.
authors: Dhananjay
authors: D
authors: Pal
authors: a Division of Pharmaceutical Sciences, School of Pharmacy , University of Missouri-Kansas City , Kansas City , MO , USA.
authors: Ashim K
authors: AK
authors: Mitra
mesh_terms: D001688:Biological Products / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D005123:Eye / Q000378:metabolism; D005128:Eye Diseases / Q000188:drug therapy*; D018014:Gene Transfer Techniques; D006801:Humans; D058449:Intravitreal Injections; D036103:Nanotechnology
chemical_list: D001688:Biological Products
keywords: Barriers; back of the eye; biologics delivery; implants; nanomicelles; nanoparticles; ocular delivery; peptide; pharmacokinetics; protein